Journal of Clinical Oncology, Vol 12, 1616-1620, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study

RP Castleberry, AB Cantor, AA Green, V Joshi, RL Berkow, GR Buchanan, B Leventhal, DH Mahoney, EI Smith and FA Hayes
University of Alabama at Birmingham.

PURPOSE: Children less than 1 year of age with metastatic neuroblastoma NB are at high risk of death. The need to identify new and effective chemotherapy agents is clear. A study was conducted by the Pediatric Oncology Group (POG) to determine the efficacy and safety of administering two courses of a single phase II agent before conventional treatment as a means to evaluate new agents in this setting. PATIENTS AND METHODS: One hundred seventy-three eligible patients more than 1 year of age with disseminated neuroblastoma received two courses of one of the following: ifosfamide (IFOS) 2 g/m2/d for 4 days intravenously (IV) plus mesna; carboplatin (CARB) 560 mg/m2 i.v. over 1 hour; iproplatin (CHIP) 325 mg/m2 IV over 2 hours; or epirubicin (EPIR) 90 mg/m2 i.v. push. Following evaluation for response and toxicity, eligible patients were randomized to receive either cisplatin 90 mg/m2 i.v. on day 1, etoposide 200 mg/m2 i.v. on day 3, cyclophosphamide 150 mg/m2/d orally on days 7 to 13, doxorubicin 35 mg/m2 i.v. on day 14 (CECA), or cisplatin 40 mg/m2 IV on days 1 to 5 and etoposide 200 mg/m2 i.v. on days 2 to 4 alternating at 3-week intervals with cyclophosphamide 150 mg/m2/d orally on days 1 to 7 and doxorubicin 35 mg/m2 IV on day 8 (HDP/VP/CA). An additional 86 patients were randomized to receive either CECA or HDP/VP/CA without initial phase II therapy. RESULTS: After phase II therapy, only 20% of patients experienced grade 3/4 hematopoietic toxicity. No toxic deaths occurred. Objective response rates (partial responses [PRs] plus minor responses [MRs]) following IFOS, CARB, CHIP, and EPIR were 70%, 77%, 67%, and 26%, respectively. Following phase III treatment, there was no statistically significant difference in rates of complete response (CR)/PR or progressive disease (PD), or in time to PD of patients who participated in the phase II window versus those who received only CECA or HDP/VP/CA. CONCLUSION: IFOS, CARB, and CHIP are efficacious in neuroblastoma, are well tolerated, and should be incorporated into primary treatment regimens. Combination regimens using these agents may be possible, since most repeat courses were given within 2 weeks. Administering phase II therapy to untreated patients with high-risk tumors provides a unique and sensitive method to assess new agents without compromising patient outcome.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Gesundheit, A. Moser, R. Or, and G. Klement Successful Antiangiogenic Therapy for Neuroblastoma With Thalidomide J. Clin. Oncol., November 20, 2007; 25(33): 5321 - 5324. [Full Text] [PDF]

				J. J. Lager, E. R. Lyden, J. R. Anderson, A. S. Pappo, W. H. Meyer, and P. P. Breitfeld Pooled Analysis of Phase II Window Studies in Children With Contemporary High-Risk Metastatic Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group J. Clin. Oncol., July 20, 2006; 24(21): 3415 - 3422. [Abstract] [Full Text] [PDF]

				R. E. George, S. Li, C. Medeiros-Nancarrow, D. Neuberg, K. Marcus, R. C. Shamberger, M. Pulsipher, S. A. Grupp, and L. Diller High-Risk Neuroblastoma Treated With Tandem Autologous Peripheral-Blood Stem Cell-Supported Transplantation: Long-Term Survival Update J. Clin. Oncol., June 20, 2006; 24(18): 2891 - 2896. [Abstract] [Full Text] [PDF]

				R. Bagatell, P. Rumcheva, W. B. London, S. L. Cohn, A. T. Look, G. M. Brodeur, C. Frantz, V. Joshi, P. Thorner, P.V. Rao, et al. Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy J. Clin. Oncol., December 1, 2005; 23(34): 8819 - 8827. [Abstract] [Full Text] [PDF]

				C. S. Kretschmar, M. Kletzel, K. Murray, P. Thorner, V. Joshi, R. Marcus, E. I. Smith, W. B. London, and R. Castleberry Response to Paclitaxel, Topotecan, and Topotecan-Cyclophosphamide in Children With Untreated Disseminated Neuroblastoma Treated in an Upfront Phase II Investigational Window: A Pediatric Oncology Group Study J. Clin. Oncol., October 15, 2004; 22(20): 4119 - 4126. [Abstract] [Full Text] [PDF]

				S. Hirschfeld, P. T.C. Ho, M. Smith, and R. Pazdur Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives J. Clin. Oncol., March 15, 2003; 21(6): 1066 - 1073. [Abstract] [Full Text] [PDF]

				W. H. Meyer, C. B. Pratt, C. A. Poquette, B. N. Rao, D. M. Parham, N. M. Marina, A. S. Pappo, H. H. Mahmoud, J. J. Jenkins, J. Harper, et al. Carboplatin/Ifosfamide Window Therapy for Osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 Trial J. Clin. Oncol., January 1, 2001; 19(1): 171 - 182. [Abstract] [Full Text] [PDF]

				M. D. Norris, S. B. Bordow, G. M. Marshall, P. S. Haber, S. L. Cohn, and M. Haber Expression of the Gene for Multidrug-Resistance-Associated Protein and Outcome in Patients with Neuroblastoma N. Engl. J. Med., January 25, 1996; 334(4): 231 - 238. [Abstract] [Full Text] [PDF]